Risk-adapted Therapy for PV
 | Risk-adapted Therapy for PV CME, CPE Jerry L. Spivak, MD, MACP | |
| Release Date: October 18, 2021 Expiration Date: October 18, 2022 | ||
Join Dr. Spivak as he discusses risk stratification and management strategies for polycythemia vera. (PV). Topics include the pathophysiology and mutational foundation of PV, predicting risk and PV prognosis, current treatment strategies and controversies, and the role of targeted therapies in managing PV. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation. | ||
| Begin, Earn CreditView Only, No Credit | ||